Zacks: Analysts Set $7.00 Target Price for STRATA Skin Sciences Inc (SSKN)
Shares of STRATA Skin Sciences Inc (NASDAQ:SSKN) have been given a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.
Brokers have set a one year consensus price target of $7.00 for the company, according to Zacks. Zacks has also assigned STRATA Skin Sciences an industry rank of 72 out of 265 based on the ratings given to its competitors.
Separately, ValuEngine upgraded shares of STRATA Skin Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, March 1st.
SSKN traded down $0.07 during midday trading on Monday, hitting $1.61. The company had a trading volume of 52,152 shares, compared to its average volume of 340,749. The company has a current ratio of 1.15, a quick ratio of 0.81 and a debt-to-equity ratio of 0.35. The stock has a market capitalization of $11.86 million, a PE ratio of 0.82 and a beta of 0.65. STRATA Skin Sciences has a twelve month low of $1.06 and a twelve month high of $3.00.
STRATA Skin Sciences (NASDAQ:SSKN) last posted its quarterly earnings data on Monday, April 2nd. The medical device company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($1.27) by $1.17. The firm had revenue of $8.60 million during the quarter, compared to analysts’ expectations of $7.35 million. STRATA Skin Sciences had a negative net margin of 60.23% and a negative return on equity of 36.19%. research analysts predict that STRATA Skin Sciences will post -1.05 EPS for the current year.
About STRATA Skin Sciences
STRATA Skin Sciences, Inc, a medical technology company, engages in developing and commercializing products for the treatment of dermatological disorders. Its products include XTRAC and VTRAC devices used for the treatment of psoriasis, vitiligo, and other skin disorders; and MelaFind system, an instrument for aiding dermatologists in the evaluation of clinically atypical pigmented skin lesions, when a dermatologist chooses to obtain additional information before making a final decision to biopsy in order to rule out melanoma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for STRATA Skin Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STRATA Skin Sciences and related companies with MarketBeat.com's FREE daily email newsletter.